PL-31 treatment of established thrombotic events in patients with cancer

Thrombosis Research

Volumn 129, Issue SUPPL. 1, 2012, Pages

  Lee, Agnes Y Y ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Anticoagulants; Deep vein thrombosis; Neoplasm; Pulmonary embolism; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; COUMARIN; CYCLOSPORIN; DABIGATRAN ETEXILATE; DALTEPARIN; DEXAMETHASONE; DOXORUBICIN; EDOXABAN; ENOXAPARIN; FONDAPARINUX; GLYCOPROTEIN P; HEPARIN; IMATINIB; LAPATINIB; LOW MOLECULAR WEIGHT HEPARIN; NILOTINIB; RIVAROXABAN; SUNITINIB; TAMOXIFEN; TINZAPARIN; VINBLASTINE; WARFARIN; FIBRINOLYTIC AGENT;

CANCER PATIENT; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; LUNG EMBOLISM; MONOTHERAPY; NEOPLASM; PRACTICE GUIDELINE; PRIORITY JOURNAL; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; ARTICLE;

ANTICOAGULANTS; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; NEOPLASMS; VENOUS THROMBOEMBOLISM;

EID: 84862145971     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/S0049-3848(12)70035-X     Document Type: Conference Paper

References (46)

1. C Kearon, SR Kahn, G Agnelli, S Goldhaber, GE Raskob, AJ Comerota Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [8th edition] Chest 133 2008 454S 545S (Pubitemid 351892971)
2. M Mandala, A Falanga, F Roila Management of venous thromboembolism [VTE] in cancer patients: ESMO Clinical Practice Guidelines Ann Oncol 22 Suppl 6 2011 vi85 vi92
3. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology Venous Thromboembolic Disease version 2.2011. Accessed Jan 10, 2012 http://www.nccn.org/professionals/physician-gls/f-guidelines.aspsupportive
4. GH Lyman, AA Khorana, A Falanga, D Clarke-Pearson, C Flowers, M Jahanzeb et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer J Clin Oncol 25 2007 5490 5505 (Pubitemid 350232226)
5. RD Hull, GF Pineo, RF Brant, AF Mah, N Burke, R Dear et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer Am J Med 119 2006 1062 1072 (Pubitemid 44826932)
6. AY Lee, MN Levine, RI Baker, C Bowden, AK Kakkar, M Prins et al. Low-molecular-weight heparin versus a coumadin for the prevention of recurrent venous thromboembolism in patients with cancer N Engl J Med 349 2003 146 153 (Pubitemid 36818784)
7. G Meyer, Z Marjanovic, J Valcke, B Lorcerie, Y Gruel, P Solal-Celigny et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study Arch Intern Med 162 2002 1729 1735
8. EA Akl, N Labedi, M Barba, I Terrenato, F Sperati, P Muti et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer Cochrane Database Syst Rev 2011 CD006650.
9. A Leizorovicz, V Siguret, D Mottier, A Leizorovicz, V Siguret, D Mottier et al. Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: the Innohep[R] in Renal Insufficiency Study [IRIS] Thromb Res 128 2011 27 34
10. EA Akl, SR Vasireddi, S Gunukula, M Barba, F Sperati, I Terrenato et al. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer Cochrane Database Syst Rev 2011 CD006649.
11. LR Zacharski, AY Lee Heparin as an anticancer therapeutic Expert Opin Investig Drugs 17 2008 1029 1037
12. N Martel, J Lee, PS Wells Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis Blood 106 2005 2710 2715 (Pubitemid 41510744)
13. TE Warkentin, MN Levine, J Hirsh, P Horsewood, RS Roberts, M Gent et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin N Engl J Med 332 1995 1330 1335
14. C Kearon, JS Ginsberg, JA Julian, J Douketis, S Solymoss, P Ockelford et al. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism JAMA 296 2006 935 942 (Pubitemid 44285370)
15. HR Buller, BL Davidson, H Decousus, A Gallus, M Gent, F Piovella et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism N Engl J Med 349 2003 1695 1702 (Pubitemid 37315006)
16. HR Buller, BL Davidson, H Decousus, A Gallus, M Gent, F Piovella et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial Ann Intern Med 140 2004 867 873
17. TE Warkentin How I Diagnose and Manage HIT Hematology Am Soc Hematol Educ Program 2011 2011 143 149
18. MJ Goldfarb, MD Blostein Fondaparinux in acute heparin-induced thrombocytopenia: a case series J Thromb Haemost 9 2011 2501 2503
19. FF van Doormaal, GE Raskob, BL Davidson, H Decousus, A Gallus, AW Lensing et al. Treatment of venous thromboembolism in patients with cancer: Subgroup analysis of the Matisse clinical trials Thromb Haemost 101 2009 762 769
20. J Trujillo-Santos, JA Nieto, G Tiberio, A Piccioli, P Di Micco, P Prandoni et al. Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry Thromb Haemost 100 2008 435 439
21. A.Y. Lee, S. Parpia, J. Julian, F.R. Rickles, M. Prins, M. Levine Risk factors for recurrent thrombosis and anticoagulant-related bleeding in cancer patients J Thromb Haemost 2009 abstract OC-MO-016. 2009.
22. G Palareti, B Cosmi, C Legnani, A Tosetto, C Brusi, A Iorio et al. D-dimer testing to determine the duration of anticoagulation therapy N Engl J Med 355 2006 1780 1789 (Pubitemid 44631361)
23. L Wawrzynska, WZ Tomkowski, J Przedlacki, B Hajduk, A Torbicki Changes in bone density during long-term administration of low-molecular-weight heparins or acenocoumarol for secondary prophylaxis of venous thromboembolism Pathophysiol Haemost Thromb 33 2003 64 67 (Pubitemid 37449280)
24. BA Hutten, MH Prins, M Gent, J Ginsberg, JG Tijssen, HR Buller Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis J Clin Oncol 18 2000 3078 3083
25. R Bauersachs, SD Berkowitz, B Brenner, HR Buller, H Decousus, AS Gallus et al. Oral rivaroxaban for symptomatic venous thromboembolism N Engl J Med 363 2010 2499 2510
26. C Luk, PS Wells, D Anderson, MJ Kovacs Extended outpatient therapy with low molecular weight heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy Am J Med 111 2001 270 273 (Pubitemid 32885621)
27. M Carrier, G Le Gal, R Cho, S Tierney et al. Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients J Thromb Haemost 7 2009 760 765
28. AY Lee Thrombosis in cancer: an update on prevention, treatment, and survival benefits of anticoagulants Hematology Am Soc Hematol Educ Program 2010 2010 144 149
29. J Hirsh, KA Bauer, MB Donati, M Gould, MM Samama, JI Weitz Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [8th Edition] Chest 133 2008 141S 159S (Pubitemid 351892966)
30. G Merli, TE Spiro, CG Olsson, U Abildgaard, BL Davidson, A Eldor et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease Ann Intern Med 134 2001 191 202
31. MR Jaff, MS McMurtry, SL Archer, M Cushman, N Goldenberg, SZ Goldhaber et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association Circulation 123 2011 1788 1830
32. RH White, H Zhou, J Kim, PS Romano A population-based study of the effectiveness of inferior vena cava filter use among patients with venous thromboembolism Arch Intern Med 160 2000 2033 2041 (Pubitemid 30437587)
33. E Brender Use of emboli-blocking filters increases, but rigorous data are lacking JAMA 295 2006 989 990
34. LS Elting, CP Escalante, C Cooksley, EB Avritscher, D Kurtin, L Hamblin et al. Outcomes and cost of deep venous thrombosis among patients with cancer Arch Intern Med 164 2004 1653 1661 (Pubitemid 39037944)
35. H Decousus, A Leizorovicz, F Parent, Y Page, B Tardy, P Girard et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group N Engl J Med 338 1998 409 415 (Pubitemid 28135667)
36. PREPIC Investigators Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC [Prevention du Risque d'Embolie Pulmonaire par Interruption Cave] randomized study Circulation 112 2005 416 422
37. T Enden, NE Klow, L Sandvik, CE Slagsvold, W Ghanima, G Hafsahl et al. Catheter-directed thrombolysis vs. anticoagulant therapy alone in deep vein thrombosis: results of an open randomized, controlled trial reporting on short-term patency J Thromb Haemost 7 2009 1268 1275
38. HS Kim, SR Preece, JH Black, LD Pham, MB Streiff Safety of catheter-directed thrombolysis for deep venous thrombosis in cancer patients J Vasc Surg 47 2008 388 394 (Pubitemid 351172671)
39. P Prandoni, AW Lensing, A Piccioli, E Bernardi, P Simioni, B Girolami et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis Blood 100 2002 3484 3488 (Pubitemid 35303914)
40. W Nicholson, WJ Nicholson, P Tolerico, B Taylor, S Solomon, T Schryver et al. Prevalence of fracture and fragment embolization of Bard retrievable vena cava filters and clinical implications including cardiac perforation and tamponade Arch Intern Med 170 2010 1827 1831
41. U.S. Food and Drug Administration Inferior vena cava [IVC] filters: Risk of adverse events with long term use. Safety Alert report issued August 9, 2010. Accessed January 10, 2012 http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm221707.htm
42. JI Weitz, J Hirsh, MM Samama New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [8th edition] Chest 133 2008 234S 256S (Pubitemid 351892968)
43. S Schulman, C Kearon, AK Kakkar, P Mismetti, S Schellong, H Eriksson et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism N Engl J Med 361 2009 2342 2352
44. MN Levine, D Deitchman, J Julian, H Liebman, C Escalante, MC O'Brien et al. A randomized phase II trial of a new anticoagulant, apixaban, in metastatic cancer J Clin Oncol 27 2009 abstract e20514.
45. van Ryn, J., Schurer, H., Kink-Eiband, M., and Clement, A. The successful reversal of dabigatrn-induced bleeding by coagluation factor concentrates in a rat tail bleeding model does not correlate with ex vivo markers of anticoagulation. Presented at American Society of Hematology Annual Meeting, December 10-13, 2011; Abstract 2316.
46. ES Eerenberg, PW Kamphuisen, MK Sijpkens, JC Meijers, HR Buller, M Levi Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects Circulation 124 2011 1573 1579